Please use this identifier to cite or link to this item:
doi:10.22028/D291-35836 | Title: | Systemic Mastocytosis Treatment with Midostaurin: [18F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome |
| Author(s): | Burgard, Caroline Rosar, Florian Khreish, Fadi Ezziddin, Samer |
| Language: | English |
| Title: | Diagnostics |
| Volume: | 12 |
| Issue: | 3 |
| Publisher/Platform: | MDPI |
| Year of Publication: | 2022 |
| Free key words: | systemic mastocytosis FDG PET/CT midostaurin tyrosine kinase inhibitor therapy outcome |
| DDC notations: | 610 Medicine and health |
| Publikation type: | Journal Article |
| Abstract: | We report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent 18FFluorodeoxyglucose ([18F]FDG) positron-emission tomography/computed tomography (PET/CT) pre- and post-6-month therapy with midostaurin, an established tyrosine kinase inhibitor. Posttherapeutic [18F]FDG PET/CT showed decreased multifocal tracer uptake in the known lesions in the gastrointestinal tract, which was consistent with relief of the patient’s symptoms and decrease in serum tryptase level. [18F]FDG PET/CT may thus be considered a potential method for monitoring the outcome of midostaurin therapy in systemic mastocytosis. |
| DOI of the first publication: | 10.3390/diagnostics12030680 |
| Link to this record: | urn:nbn:de:bsz:291--ds-358360 hdl:20.500.11880/32682 http://dx.doi.org/10.22028/D291-35836 |
| ISSN: | 2075-4418 |
| Date of registration: | 29-Mar-2022 |
| Faculty: | M - Medizinische Fakultät |
| Department: | M - Radiologie |
| Professorship: | M - Prof. Dr. Samer Ezziddin |
| Collections: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Files for this record:
| File | Description | Size | Format | |
|---|---|---|---|---|
| diagnostics-12-00680.pdf | 926,59 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
